🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

672 results for “Nan” Clear

  1. Recombinant human thrombopoietin

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Liver Cirrhosis

    phase 1 small molecule active

    1 trial

  2. Recombinant human tissue kallikrein

    DiaMedica Therapeutics

    Stroke

    phase 1 small molecule completed

    1 trial

  3. Recombinant oncolytic herpes simplex virus type Ⅰ (R130)

    Shanghai University of Traditional Chinese Medicine

    Osteosarcoma

    phase 1 small molecule active

    1 trial

  4. Recombinant von Willebrand factor : recombinant FVIII (rVWF:rFVIII)

    Takeda

    Von Willebrand Disease

    phase 1 mab completed

    1 trial

  5. SHR-1501

    Jian Li

    Advanced Malignancies

    phase 1 small molecule completed

    1 trial

  6. SPGL008

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Advanced Malignant Tumors

    phase 1 small molecule active

    1 trial

  7. SSGJ-612

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Advanced Malignant Tumors

    phase 1 small molecule active

    1 trial

  8. SSGJ-709

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Advanced Malignant Tumors

    phase 1 small molecule active

    1 trial

  9. SSS59

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Malignant Tumors

    phase 1 small molecule active

    1 trial

  10. STK-002

    Stoke Therapeutics

    Autosomal Dominant Optic Atrophy

    phase 1 small molecule active

    1 trial

  11. SYS6055

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed/Refractory B-Cell Malignancies

    phase 1 small molecule active

    1 trial

  12. Sapanisertib

    Takeda

    Non-hematologic Malignancy

    phase 1 small molecule completed

    1 trial

  13. Single-Ascending Doses of 2-Methoxyestradiol in Healthy Non-Pregnant Female Subjects.

    Laboratorios Tillomed Spain S.L.U

    No medical condition.

    phase 1 other active

    1 trial

  14. Sonrotoclax

    BEONE MEDICINES AUS PTY LTD

    Mature B-Cell Malignancies

    phase 1 small molecule active

    1 trial

  15. Study of BGB-11417 in Patients with Mature B Cell Malignancies

    BEONE MEDICINES AUS PTY LTD

    Mature B Cell Malignancies

    phase 1 other active

    1 trial

  16. Study of PIT565 in relapsed and/or refractory B-cell malignancies

    Novartis Pharmaceuticals

    Relapsed and/or refractory B-cell Non-Hodgkin lymphoma (R/R B-NHL) and relapsed and/or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL)

    phase 1 other active

    1 trial

  17. Study of REGN6569 and Cemiplimab in Adult Patients with Advanced Solid Tumor Malignancies

    Lacuna Pharma Pty Ltd

    Squamous Cell Carcinoma of Head and Neck

    phase 1 other active

    1 trial

  18. Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

    AbbVie Deutschland GmbH & Co. KG

    Select B-Cell malignancies.

    phase 1 other active

    1 trial

  19. Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

    Lacuna Pharma Pty Ltd

    B-cell non-Hodgkin lymphoma (NHL)

    phase 1 other active

    1 trial

  20. Sunitinib, Pemetrexed

    Pfizer

    Neoplasm, Malignant

    phase 1 small molecule completed

    1 trial

  21. T cell injection targeting CD7 chimeric antigen receptor

    The First People's Hospital of Lianyungang

    CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies

    phase 1 mab active

    1 trial

  22. T3011

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Malignant Ascites

    phase 1 small molecule active

    1 trial

  23. TAK-164

    Takeda

    Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies

    phase 1 small molecule terminated

    1 trial

  24. TAK-228

    Takeda

    Advanced Nonhematologic Malignancies

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources